FDA Hearing. What FDA Failed to Disclose: 1991, 2006.
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent.
18 Deaths Linked to drug – Serzone Removed from European market, not US Fri, 17 Jan 2003 Bloomberg News reported that the antidepressant, Serzone had been linked to 25 cases of liver damage and 18 deaths. On Jan 8, 2003 European authorities removed the drug from the European market. On…
Congressional Hearing: What did drug companies & FDA hide? Fri, 16 Jul 2004 AHRP has learned that the Congressional hearing by the House Subcommittee on Oversight and Investigations, scheduled for Tuesday, July 20, 2004 at 9:30 AM, will have a line up of major pharmaceutical industry executives who will be…
Cong Hinchey PRESS CONFERENCE Re: Drug Co. Influence on FDA Sat, 10 Jul 2004 New York Congressman Maurice Hinchey (House Appropriations Committee) is holding a press conference on Tuesday, July 13, 2004, at 10:30 AM to address issues of concern about undue influence by drug manufacturers on FDA policy and…
One has to wonder why discovery of defective cars are front page news while defective FDA-approved prescription drugs are accepted as part of life’s risk.
Canadian Regulators Withdraw ADD Drug Linked to 20 Sudden Deaths Thu, 10 Feb 2005 Canadian regulators – but not the FDA – have withdrawn a Adderall, a pssychostimulant drug prescribed for children with so-called ADHD that has been linked to 20 sudden deaths linked to the drug – of which…